These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26642099)

  • 1. Current issues in the economics of vaccination against dengue.
    Tozan Y
    Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative.
    Lim JK; Lee YS; Wilder-Smith A; Thiry G; Mahoney R; Yoon IK
    Expert Rev Vaccines; 2016; 15(4):529-38. PubMed ID: 26651238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financing dengue vaccine introduction in the Americas: challenges and opportunities.
    Constenla D; Clark S
    Expert Rev Vaccines; 2016; 15(4):547-59. PubMed ID: 26690087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of dengue vaccination in ten endemic countries.
    Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
    Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of health economic evaluation studies of dengue vaccines.
    de Soárez PC; Silva AB; Randi BA; Azevedo LM; Novaes HMD; Sartori AMC
    Vaccine; 2019 Apr; 37(17):2298-2310. PubMed ID: 30910406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore.
    Carrasco LR; Lee LK; Lee VJ; Ooi EE; Shepard DS; Thein TL; Gan V; Cook AR; Lye D; Ng LC; Leo YS
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1426. PubMed ID: 22206028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the clinical development of a dengue vaccine.
    Wallace D; Canouet V; Garbes P; Wartel TA
    Curr Opin Virol; 2013 Jun; 3(3):352-6. PubMed ID: 23747120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
    Lam SK
    Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
    Coudeville L; Baurin N; L'Azou M; Guy B
    Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review.
    Supadmi W; Suwantika AA; Perwitasari DA; Abdulah R
    Value Health Reg Issues; 2019 May; 18():132-144. PubMed ID: 31082793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Dengue Vaccine Communication and Advocacy: Challenges and Way Forward.
    Carvalho A; Van Roy R; Andrus J
    Expert Rev Vaccines; 2016; 15(4):539-45. PubMed ID: 26855170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review.
    Endo IC; Ziegelmann PK; Patel A
    Vaccine; 2016 Dec; 34(50):6133-6147. PubMed ID: 27810313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.
    Guy B
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
    Lee JS; Lourenço J; Gupta S; Farlow A
    Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
    Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
    Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dengue vaccination in Puerto Rico.
    España G; Leidner AJ; Waterman SH; Perkins TA
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009606. PubMed ID: 34310614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
    España G; Yao Y; Anderson KB; Fitzpatrick MC; Smith DL; Morrison AC; Wilder-Smith A; Scott TW; Perkins TA
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007482. PubMed ID: 31260441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.
    Douglas DL; DeRoeck DA; Mahoney RT; Wichmann O
    PLoS Negl Trop Dis; 2013; 7(3):e2127. PubMed ID: 23516658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.